Zhongbo Ruikang is a provider of cellular immunotherapy products and testing services, focusing on the screening, diagnosis, treatment and health management of tumors, cardiovascular and cerebrovascular diseases, immune diseases, elderly and other diseases. Tumor cell immune technology, EAAL-amplified activated autologous lymphocyte technology and other technologies have developed a variety of cellular immunotherapy products, and also provided users with tumor antigen detection, circulating tumor cells and DNA detection and other early tumor screening services. Recently announced the completion of tens of millions of yuan in A+ round of financing. This round of financing was led by Hi-Tech Xinjun.
This article is reproduced from: https://www.itjuzi.com/investevent/13350567
This site is for inclusion only, and the copyright belongs to the original author.